Regorafenib to keep bone cancer from coming back
Part of Bones, joints & muscles, Cancer clinical trials.
This trial studies whether regorafenib given after first treatment helps patients with bone sarcoma stay in remission longer. It focuses on safety and whether the medicine can prevent the cancer from growing or returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) are at least 12 years old when you sign consent
- Your bone sarcoma diagnosis is confirmed by pathology (biopsy/tissue testing)
- After completing standard chemotherapy for your cancer type, you have no clear cancer—or you have complete remission
- It has been at least 4 weeks and no more than 2 months since your last chemotherapy dose
- Your recent scans show no more than tiny, allowed lung nodules (or they are not considered true spread)
- Your blood tests, kidney/liver labs, and recovery from prior treatment are within allowed limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether regorafenib, given after your main treatments, can help keep high-grade bone sarcoma from coming back or progressing. It checks safety and whether this “maintenance” approach works better than best supportive care alone.
This trial tests a pill called sulfatinib for young people with bone cancer (osteosarcoma) that has come back or not responded to standard treatments. Sulfatinib works by cutting off the blood supply that tumors need to grow, and the goal is to see if it can control the cancer.
This study tests two treatments for high-risk osteosarcoma (a bone cancer). It compares mifamurtide plus standard treatment versus sorafenib plus standard treatment to see which is safer and more effective.
This study tests a combination of two drugs, cabozantinib and ifosfamide, for sarcomas that have come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial tests a combination of regorafenib (a targeted pill that cuts off blood supply to tumors) with a low-dose, continuous chemotherapy regimen for people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if this mix can slow or stop the cancer's growth.
Hear when a new Bone Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.